

1614




PATENT
Docket No.: 27129/36739A

TECH CENTER 1600/280

OCT 15 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: King <i>et al.</i>)	I hereby certify that this paper and
Serial No.: 10/006,557)	documents referred to as enclosed
Filed: December 3, 2001)	herewith are being deposited with
For: Modulation of Pericyte Proliferation)	United States Postal Service as First
Group Art Unit: 1614)	Class Mail, postage prepaid, in an
Examiner: To be assigned)	envelope addressed to:
)	Commissioner for Patents,
)	Washington, D.C. 20231, on this
)	date:
)	October 8, 2002
)	
)	
)	
)	Jeffrey S. Sharp
)	Reg. No.: 31,879
)	Attorney for Applicants

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§1.56 AND 1.97 AND 1.98(d)**

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In compliance with 37 C.F.R. §1.97 and the duty of disclosure under 37 C.F.R. §1.56, the attached form PTO-1449 is hereby submitted by the Applicants for consideration in connection with the above-identified patent application. Copies of documents A1-A41, B1-B11, and C1-C12 are enclosed.

Documents A7, B2, B10-B11, C5, and C8 were identified in an International Search Report, a copy of which is enclosed as document C12, from the European Patent Office in a related international application (PCT/US01/46609).


This Information Disclosure Statement is not intended to be an admission that a search has been made, that other relevant art does not exist, or that any of the information disclosed herein constitutes prior art under 35 U.S.C. §102 or §103.

No fee is believed to be due under 37 C.F.R. §1.97(b) because this statement and Form PTO-1449 are being submitted before receipt of a first official action on the merits in the above-identified patent application. If required, however, any fee may be charged to Deposit Account 13-2855.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6357
(312) 474-6300

October 8, 2002

By: 
Jeffrey S. Sharp
Registration No.: 31,879



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	1	of	2	Application Number	10/006,557
				Filing Date	December 3, 2001
				First Named Inventor	King et al.
				Art Unit	1614
				Examiner Name	To be assigned
				Attorney Docket Number	27129/36739A

Complete if Known

TECH CENTER 1600/2900

OCT 15 2002

RECEIVED


U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number-Kind Code ² (if known)		
	A1	5,198,541	03-30-1993	Elsbach et al.
	A2	5,348,942	09-20-1994	Little et al.
	A3	5,420,019	05-30-1995	Theofan et al.
	A4	5,447,913	09-05-1995	Ammons et al.
	A5	5,494,896	02-27-1996	John F. Hansbrough
	A6	5,523,288	06-04-1996	Cohen et al.
	A7	5,578,568	11-26-1996	Ammons et al.
	A8	5,578,572	11-26-1996	Horwitz et al.
	A9	5,627,153	05-06-1997	Little et al.
	A10	5,639,727	06-17-1997	Roger G. Little
	A11	5,641,874	06-24-1997	Elsbach et al.
	A12	5,643,570	07-01-1997	Theofan et al.
	A13	5,643,875	07-01-1997	Friedmann et al.
	A14	5,652,332	07-29-1997	Roger G. Little
	A15	5,646,114	07-08-1997	Lewis H. Lambert, Jr.
	A16	5,674,834	10-07-1997	Theofan et al.
	A17	5,703,038	12-30-1997	Ammons et al.
	A18	5,733,872	03-31-1998	Roger G. Little
	A19	5,741,779	04-21-1998	White et al.
	A20	5,753,620	05-19-1998	Friedmann et al.
	A21	5,756,464	05-26-1998	Scannon et al.
	A22	5,763,567	06-09-1998	Roger G. Little
	A23	5,783,561	07-21-1998	Horwitz et al.
	A24	5,807,818	09-15-1998	Roger G. Little
	A25	5,827,816	10-27-1998	Theofan et al.
	A26	5,837,678	11-17-1998	Roger G. Little
	A27	5,851,802	12-22-1998	March D. Better
	A28	5,854,214	12-29-1998	Roger G. Little
	A29	5,856,302	01-05-1999	Ammons et al.
	A30	5,856,438	01-05-1999	Roger G. Little
	A31	5,858,974	01-12-1999	Little et al.
	A32	5,888,973	03-30-1999	Lewis H. Lambert, Jr.
	A33	5,888,977	03-30-1999	Giroir et al.
	A34	5,935,930	08-10-1999	White et al.
	A35	5,945,399	08-31-1999	Scannon et al.
	A36	5,948,408	09-07-1999	Elsbach et al.
	A37	5,952,302	09-14-1999	Friedmann et al.
	A38	5,980,897	11-09-1999	Elsbach et al.
	A39	5,990,086	11-23-1999	Giroir et al.
	A40	6,013,629	01-11-2000	Lewis H. Lambert, Jr.
	A41	6,013,631	01-11-2000	Horwitz et al.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
				Application Number	10/006,557
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Filing Date	December 3, 2001
				First Named Inventor	King et al.
				Art Unit	1614
				Examiner Name	To be assigned
				Attorney Docket Number	27129/36739A
Sheet	2	of	2		

TECH CENTER 1600/2900

OCT 15 2002

RECEIVED

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)		
	B1	WO 89/01486	02-23-1989	New York University
	B2	WO 94/20128	09-15-1994	XOMA Corporation
	B3	WO 95/08344	03-30-1995	XOMA Corporation
	B4	WO 95/19179	07-20-1995	XOMA Corporation
	B5	WO 95/19180	07-20-1995	XOMA Corporation
	B6	WO 96/01647	01-25-1996	XOMA Corporation
	B7	WO 97/04008	02-06-1997	XOMA Corporation
	B8	WO 97/42966	11-20-1997	XOMA Corporation
	B9	WO 98/06415	02-19-1998	XOMA Corporation
	B10	WO 00/43028	07-27-2000	XOMA Technology Ltd.
	B11	WO 01/00655	04-01-2001	XOMA Technology Ltd.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	C1	Doherty et al., "Gene Expression during Vascular Pericyte Differentiation," <i>Critical Review in Eukaryotic Gene Expression</i> , 9:1-17 (1999).
	C2	Elsback et al., "Separation and Purification of a Potent Bactericidal/Permeability-increasing Protein and a Closely Associated Phospholipase A ₂ from Rabbit Polymorphonuclear Leukocytes," <i>The Journal of Biological Chemistry</i> , 254:11000-11009 (1979).
	C3	Elsbach et al., "Oxygen-Independent Antimicrobial Systems of Phagocytes," <i>Inflammation: Basic Principles and Clinical Correlates</i> , 603-636 (1992).
	C4	Hu et al., "The effect of heparin on the haemodynamic and structural response in the rat to acute and chronic hypoxia," <i>Br. J. Exp. Path.</i> , 70:113-124 (1989).
	C5	Khoury et al., "Effects of Endotoxin on Lung Pericytes in Vitro," <i>Microvascular Research</i> , 56:71-84 (1998).
	C6	Khoury et al., "Heparin-Like Molecules Inhibit Pulmonary Vascular Pericyte Proliferation in vitro," <i>Am. J. Physiol. Lung Cell. Mol. Physiol.</i> , 279:L252-L261 (2000).
	C7	Ooi et al., "Endotoxin-neutralizing Properties of the 25 kD N-Terminal Fragment and a Newly Isolated 30 kD C-Terminal Fragment of the 55-60 kD Bactericidal/Permeability-increasing Protein of Human Neutrophils," <i>J. Exp. Med.</i> , 174:649-655 (1991).
	C8	Rauniyar et al., "Compounds Derived from Human Bactericidal/Permeability Increasing Protein Suppress VEGF-Induced Retinal Endothelial Cell Growth and Hypoxia-Induced Retinal Neovascularization while Enhancing Retinal Pericyte Growth," <i>Investigative Ophthalmology & Visual Science</i> , 42:S243 (2001).
	C9	Rhodin et al., "Capillary growth in the mesentery of normal young rats. Intravital video and electron microscope analyses," <i>J. Submicrosc. Cytol. Pathol.</i> , 21:1-34 (1989).
	C10	Sims, "Experimental Biology 2000 Symposium on Capillaries: How their structure and function can alter to meet tissue demands," <i>Clinical and Experimental Pharmacology and Physiology</i> , 27:842-846 (2000).
	C11	Weiss et al., "Cellular and Subcellular Localization of the Bactericidal/Permeability-Increasing Protein of Neutrophils," <i>Blood</i> , 69:652-659 (1987).
	C12	International Search Report, PCT.US01/46609, European Patent Office Search Authority.
Examiner Signature		Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.